Ki67 Labelling Index predicts clinical outcome and survival in oral squamous cell carcinoma by Gadbail, Amol Ramchandra et al.
J Appl Oral Sci.
Abstract
Submitted: September 12, 2020
Modification: November 3, 2020
Accept: November 19, 2020
Ki67 Labelling Index predicts 
clinical outcome and survival in oral 
squamous cell carcinoma
Objective: To investigate the Ki 67 expression and its correlation with 
clinicopathological features and 3 years as well as 5 years survival rate in 
oral squamous cell carcinoma (OSCC). Methodology: Total 217cases of OSCC 
primarily treated with surgery with or without radiation were included. All 
patients were followed up for 3 years and 150 were followed up of 5 years for 
disease free survival. The immunohistochemistry was carried out on neutral 
buffered formalin fixed paraffin embedded tissue to evaluate the expression 
of Ki67. Results: The Ki67 labeling index (LI) was significantly higher with 
respect to adverse clinicopathological parameters such as histopathological 
grading (p<0.001), clinical TNM staging (p<0.001) and nodal metastasis 
(p<0.001). The OSCC patients survived for less than 3 and 5 years were 
showed significantly higher Ki67 LI as compared to diseases free survived 
more than 3 and 5 years(p<0.001). The three years survival rate of OSCC 
patient significantly higher with low Ki67 LI (≤45) 96.2%, followed by 
moderate Ki67 LI (46 to 60) 60.7% and high Ki67 LI (≥61) 37.7% (p<0.001). 
The five years survival rate of OSCC patient statistically significantly higher 
with low Ki67 LI (≤45)93.3%, followed by moderate Ki67 LI (46 to 60) 46.8% 
and Ki67 LI (≥61) 23.3%  (p<0.001). Conclusion: The measurement of cell 
proliferative activity by using Ki67 antigen expression in individual OSCC 
might provide unique, predictive information on clinical outcome, prognosis 
and deciding treatment modalities in OSCC.
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Introduction
Globally, oral squamous cell carcinoma (OSCC) 
incidence is 2.7 in 100000 populations. In south-
central Asia, the incidence of OSCC cases was highest 
that is40.9% of all incident cases of OSCC and often 
associated poor prognosis due to high morbidity 
and mortality rate.1OSCC is extensively investigated 
for identification and validation of prognostic and 
predictive markers. However, up until this point, no 
single marker is consistently acknowledged for routine 
clinical use in OSCC patients.2
Cell proliferation is viewed as a key fundamental 
biological process in the growth and development 
as well as upkeep of homeostasis of tissue. The 
biological behavior of tumor such as local invasion/
expansion, local recurrence, metastatic potential as 
well as disease free survival is predicted by assessment 
of cell proliferation in histopathology by means of 
immunohistochemical evaluation.3 Thus, evaluation 
of proliferative status is conventionally viewed as 
helpful tool in deciding the biological aggressiveness 
of any tumor. 
Ki67 is a large non-histone protein present in the 
nucleus and nucleolar region, which is seen in cells 
undergoingproliferation.4 Ki67 antigen expression 
is a reliable and potent biomarker for the accurate, 
simple and prompt identification of the fraction of cells 
with proliferative potential in a tumor.5 Higher Ki67 
expression is an indicator of tumor cells with higher 
proliferation and locally invasive potential and thus 
providing one of the best markers for the evaluation 
of biological aggressiveness of tumor.6
Ki67 expression has been accounted to provide 
a diagnostic and poor prognostic biomarker for 
OSCC patients.7-9 Despite several efforts made in the 
literature, still there is a controversy existed for Ki-67 
being utilized as the proliferation capacity of cancer 
cells as a predictive biomarker for tumor grade, nodal 
metastasis, clinical TNM stage and survival rate. 
Xie,  et al.10 (2016) carried out meta-analysis on 
prognostic implication of Ki-67 expression in OSCC 
and recommended further studies on Ki67 expression 
with five-year survival rate by using standardized 
immunohistochemistry protocols needed to further 
strengthen its role as diagnostic and prognostic 
predictive marker.  
Looking at the mandate of five-year survival 
analysis, the present study was designed to investigate 
immunohistochemical expression of Ki67 in OSCC with 
primary focus on three as well as five years survival 
rate and to assess its predictive value on clinical 
outcome. These new objectives were investigated on 
the samples, which were utilized in our previously 
published papers.11,12
Methodology
The present study was conducted at the Sharad 
Pawar Dental College and Hospital, Wardha, 
Maharashtra, India. Institutional ethics committee of 
Datta Meghe Institute of Medical Sciences, Deemed 
to be University, Wardha, India was granted the 
ethical approval for the present study (Ref no. DMIMS 
(DU)/IEC/2014-15/953, dated 15/12/2014).The 
written consent was obtained from the patient, who 
participated in this study. 
The study population was retrieved from year 
2010 to 2015, which was previously utilized for our 
research publications11,12 with different objectives. The 
clinically diagnosed and histologically confirmed 217 
cases of OSCC, who fulfilled inclusion and exclusion 
criteria’s, were included. All retrieved cases were 
primarily treated with wide local surgical excision 
with normal margins and cervical neck dissection 
with or without radiation. Patients with coexisting 
malignancy, previous history of oropharyngeal or 
oral or any other head and neck cancer, recurrent or 
distant disease, any other systemic diseases, and pre-
operative chemotherapy, radiotherapy, or surgery were 
excluded from the study. Dissected cervical lymph 
nodes obtained from surgically excised specimens 
were examined histopathologically for confirmation of 
lymph node metastasis. The clinical TNM staging of all 
OSCC patients were done by using the American Joint 
Committee of Cancer13 clinical TNM staging system 
for oral and oropharyngeal cancer. The clinical TNM 
staging was further broadly categories for OSCC cases 
into early clinical TNM stage (I and II) and advanced 
clinical TNM stage (III and IV). Demographic details 
along with clinical features, relevant habit history, 
and operative details were obtained. Disease free 
survival of 3 years as well as for some cases 5 years 
was recorded on follow up.
Study design
As recommended by Dissanayake, et al.14 (2003) 
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neoplastic cells from invasive tumor front region are 
more informative in studying cell proliferation markers. 
The histopathological slides of incisional biopsy as well 
as from resected specimen of OSCC were examined 
by three oral pathologists independently and those 
sections showing invasive tumor front of OSCC were 
utilized for immunohistochemical evaluation of Ki67 
antigen expression. All the hematoxylin and eosin 
stained histopathology and IHC (Ki67) slides were 
blinded for microscopic analysis. All the included 
cases were confirmed for histopathological diagnosis 
of squamous cell carcinoma and were classified in 
to well-differentiated SCC (WDSCC), moderately-
differentiated SCC (MDSCC) and poorly-differentiated 
SCC (PDSCC). Similarly, three oral pathologists, who 
were blinded for histopathological grading status 
of OSCC cases, were independently performed IHC 
scoring of Ki67. The obtained IHC score for Ki67 were 
then computed for all OSCC.
Immunohistochemistry 
The standard procedure of immunohistochemistry 
(IHC) was done for Ki67, by utilizing appropriate 
controls on neutral buffered formalin fixed paraffin 
embedded tissue. The tissue sections were treated with 
01 mol/L sodium citrate buffer (pH 6.0) in microwave 
oven for 10 minute followed by bench-cooled for 20 
min, and again the same cycle was repeated for the 
antigen retrieval. Endogenous peroxidase activities 
of the tissue were blocked by incubating the tissue 
sections with 3% H2O2 in methanol for 30 minutes. 
The non-specific tissue reactions were prevented 
by incubating the tissue sections with 10% serum 
for 10 minutes. For IHC detection of Ki67 antigen, 
pre-diluted Monoclonal Mouse Anti-Human, Ki67 
antibody [clone MIB-1; Product code:N1633; Dako, 
Denmark (DD)], was incubated with tissue sections 
at room temperature in a humidifying chamber for 
60 minutes. Known hyperplastic lymph node was 
used as a positive control for Ki-67. One section from 
positive control was used as the negative control by 
omitting the primary antibody and by incubating with 
serum. The horseradish peroxidase labeled polymer 
anti-mouse secondary antibody (DakoEnVision 
System, Product code:K4000, DD) against the primary 
antibody was incubated at room temperature in 
humidifying chamber for 30 minutes. To visualized 
Ki67 antigen antibody complex (expression), the 
freshly prepared substrate/chromogen solution of 3, 
30 Diaminobenzidine (DAB) in provided buffer was 
used and counterstained in Mayer’s hematoxylin.15 The 
brown coloration of nucleus indicates the positivity for 
Ki67 antigen expression, where as the blue color of 
nucleus due to counterstained in Mayer’s hematoxylin 
indicates the Ki67 negative cells.
Immunohistochemistry scoring
Neoplastic epithelial cells were viewed as positive 
for the Ki67 antigen expression, if intranuclear DAB 
staining (brown color) was observed. Every single 
stained nuclei were counted positive irrespective of 
intensity of staining. Invasive tumor front areas as 
well as areas with highest density of Ki67 labeled 
neoplastic epithelial cells were located by screening 
the IHC sections at a 100 X magnification by Leica 
DM LB2 microscope. In the most heavily Ki67 labeled 
areas, Ki67 positive neoplastic epithelial cell counts 
were carried outin 5 randomly selected fields at 
400 X magnification. Minimum of 1000Ki67 labeled 
neoplastic epithelial cells were counted in each section. 
The number of positively stained nuclei was measured 
as a percentage of the total number counted neoplastic 
epithelial cells. Ki67 labeling index (LI) was derived 
as number positive cells for Ki67 multiplied by 100 
and divided by total number observed neoplastic 
epithelial cells. Based on median and also considering 
the frequency distribution KI67 LI, cut off values for 
KI67 LI were generated for three groups to avoid 
the formation of very small and too many groups.9 
Thus, based on the KI67 LI, the Ki67 expression were 
categorized in to low: Ki67 LI≤45, moderate: Ki67 LI 
46 to 60 and high: Ki67 LI ≥61. 
Statistical analysis
The data were statistically analyzed using SPSS, 
version 17.0 for Windows. One-way ANOVA and Tukey’s 
HSD test were utilized to find out the differences of 
Ki67 LI amongst the various histopathological grades, 
clinical TNM stage, and sites of OSCC. Independent 
student t test was applied to find out the differences 
of KI67 LI between metastatic and non-metastatic, 
early and advanced clinical TNM stage, survived and 
not survived less than 3 year, and survived and not 
survived less than 5 years. KaplanMeier survival curves 
as well as the longrank test were used to estimate 
and compare disease free 3 and 5 years survival with 
low, moderate and high Ki67 LI. The level of statistical 
significance was at p<0.05.
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Results
Details of demographic and clinicopathological 
features of oral squamous cell carcinoma
Total 217 OSCC patients were included in this study, 
who were fulfilled the inclusion and exclusion criteria. 
OSCC cases were predominantly seen in males 159 
(73.27%) with male to female 35 (26.72%) ratio was 
4.54:1.The age of OSCC patients were ranges from 20 
years to 79 years and the mean age of OSCC patient 
was 50.25 (±12.14) years. The most common site 
for OSCC was buccal mucosa 84(38.70%) followed 
by gingivobuccal sulcus 69 (31.79%), tongue 24 
(11.05%), retromolar region 16 (7.37%), labial 
Mucosa 11 (5.06%), palate 10 (4.60%) and floor of 
mouth 3 (1.38%). Tobacco lime and betel nut (TLB) 
135 (62.21%) was the most common habit noted 
in OSCC patient followed by tobacco lime (TL) 45 
(20.73%) and Betel nut (BN) 33 (15.20%). Nearly 
95% cases of OSCC were MDSCC 106 (48.84%) 
and WDSCC 100 (46.08%).  MDSCC were the most 
common histopathological type of OSCC. PDSCC were 
found in 11 (5.06%) cases of OSCC. Clinical TNM stage 
IV was the most commonly observed in 94 (43.31%) 
OSCC followed by Stage III 55 (25.34%) to stage 
II 52 (23.96%) and stage I 16 (7.37%). Advanced 
clinical TNM stage was observed in 149 (68.66%) 
OSCC and early clinical TNM stage was observed in 68 
Characteristics OSCC (n = 217)
Age
Mean (SD) 50.25 (±12.14)





Buccal Mucosa 84 (38.70%)




Labial Mucosa 11 (5.06%)






Tobacco and lime 45 (20.73%)
Tobacco lime and Betel nut 135 (62.21%)
Betel nut 33 (15.20%)
No habits 4 (1.84%)
Clinical TNM Stage
Stage I 16 (7.37%)
Stage II 52 (23.96%)
Stage III 55 (25.34%)
Stage IV 94 (43.31%)
Clinical TNM Stage
Early Stage 68 (31.33%)




3 years disease free survival (n=217)
Non-survived 69 (31.79%)
Survived 148 (68.20%)
5 years disease free survival (n=150)
Non-survived 69 (46.00%)
Survived 81 (54.00%)
Note:- OSCC: Oral squamous cell carcinoma, WDSCC: Well differentiated squamous cell carcinoma, MDSCC: Moderately differentiated 
squamous cell carcinoma, PDSCC: Poorly differentiated squamous cell carcinoma, SD: standard deviation, TNM: Tumor (T) Nodes (N) 
and Metastasis (M).
Table 1- Details of demographic and clinicopathological parameters of oral squamous cell carcinoma patients
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(31.33%) OSCC. The cervical lymph node metastasis 
was found in 68 (31.33%) OSCC cases. All 217 cases 
were followed up for 3 years and 148 (68.20%) cases 
of OSCC were survived. A five year follow up data of 
150 cases were available and 81 (54.00%) OSCC cases 
found to be survived (Table 1).
Association of Ki67 LI with clinicopathological 
parameters of oral squamous cell carcinoma
Statistically significant variations of mean Ki67 LI 
were found among all groups of OSCC (p<0.001). Ki67 
LI were observed statistically significantly in ascending 
order from WDSCC 43.72 (±5.28) to MDSCC 59.41 
(±9.75) to PDSCC 74.59 (±9.20) (p<0.001) (Figure 
1) (Table 2).
Statistically significant variations of mean Ki67 
LI were found among clinical TNM Stage I, Stage II, 
Stage III, and Stage IV of OSCC (p<0.001). There was 
statistical significant difference for Ki67 LI observed 
between Stage III 51.83 (±10.15) and Stage IV 57.17 
(±11.71) (p=0.034); Stage I 46.54 (±9.35) and 
Stage IV 57.17 (±11.71) (p=0.004); Stage II 48.47 
(±12.99) and Stage IV 57.17 (±11.71) (p<0.001). The 
mean of Ki67 LI were statistically significantly higher 
in Advanced TNM stage55.20 (±11.42) as compared 
to Early Stage48.01 (±12.19) of OSCC (p<0.001) 
(Table 2).
There was no statistical significant variations of 
mean of Ki67 LI found among various sites of OSCC 
(P=0.374). However, the Ki67 LI was marginally 
higher in Palate 56.28 (±13.89) followed by Floor of 
mouth 55.28 (±15.09), Retromolar 55.89 (±6.64), 
Gingivo-buccal Sulcus 53.74 (±11.82), Tongue 53.50 
(±14.43), Buccal Mucosa 52.04 (±12.34) and Labial 
Mucosa 45.79 (±9.66) (Table 2).
The mean of Ki67 LI were statistically significantly 
higher in Metastatic 60.23 (±10.99) as compared 
to non-metastatic 49.03 (±10.83) cases of OSCC 
(p<0.001).
The relationship between Ki67 LI with 3 and 5 
years disease free survival of oral squamous 
cell carcinoma patients
On 3 years of follow up of for disease free survival, 
the mean of Ki67 LI were statistically significantly 
higher in Non-survived 60.82 (±10.64) as compared 
to survived cases 49.28 (±10.97) of OSCC (p<0.001). 
Similarly on 5 years of follow up of for disease free 
survival, the mean of Ki67 LI were statistically 
significantly higher in Non-survived 60.82 (±10.64) as 
compared to survived cases 49.25 (±10.20) of OSCC 
(p<0.001) (Table 2).
The three years survival rate of OSCC patient 
statistically significantly higher with Ki67 LI 
≤45(96.2%), followed by Ki67 LI of 46 to 60 (60.7%) 
and Ki67 LI of ≥61(37.7%) (p<0.001) (Figure 2) 
(Figure 3). The five years survival rate of OSCC patient 
statistically significantly higher with Ki67 LI of ≤45 
(93.3%), followed by Ki67 LI of 46 to 60 (46.8%) and 
Ki67 LI of ≥61 (23.3%) (p<0.001) (Figure 4) (Table 3).
Figure 1- Photomicrograph showing Ki67 antigen expression 
(Ki67 labeling index) in a) Well differentiated squamous 
cell carcinoma, b) Moderately differentiated squamous cell 
carcinoma, c) Poorly Moderately differentiated squamous cell 
carcinoma (Immunohistochemistry; Magnification X100)
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Discussion 
OSCC is an aggressive neoplasm with unpredictable 
biological behavior. This results in unfavorable 
prognosis leading to functional impairment as well as 
high mortality rate irrespective of type of treatment 
modality rendered.16 Treatment modalities and 
prognosis for OSCC were routinely determined based 
on clinical features such as tumor size, cervical 
metastasis to lymph node, distant metastasis and 
histopathological features mainly histological grade 
with other characteristics such as mitotic activity, 
vascular or perineural invasion.17 Recently, numerous 
studies observed that the clinico pathological factors 
such as advanced age, lymph node metastasis, 
advanced TNM stage, advanced histopathological 
grade, the presence of perineural invasion, vascular 
invasion, tumour–stroma ratio (TSR) and tumour 
budding were predicator of poor survival in OSCC 
patients.18-22 Despite of their claimed usefulness in 
various studies, characterization of OSCC that are at 
higher risk for recurrence and relapse is major concern. 
However, use of cost effective, easy and widely use 
immunohistochemistry to assess molecular markers 
leads to an increased understanding of biological 
behavior of OSSC. With the use of molecular markers 
predicting biological aggressiveness, locoregional 
recurrence and survival are useful in identification 
of patients, who needs more individualized intensive 
treatment regimes such as chemotherapy and 
radiotherapy in addition to surgery. An increasing 
number of studies, have revealed that Ki67 as a 
reliable cell proliferation biomarker was unregulated 
in numerous tumors and may be used as an important 
factor in cancer grading and prognostic evaluation.23 
Thus, in this study we evaluated Ki67 expression in 
invasive front region of OSCC with a lager cohort of 
217 cases and K67 expression was also correlated 
with clinical outcome and three as well as five years 
disease free survival. 
In this study, we assess the cut of range value for 
Ki67 LI as low, moderate and high with respect to three 
Parameters Groups N Mean Sta. Dev. Tukey HSD test/ Independent Samples T Test
Histopathological 
Grading
WDSCC (A) 100 43,72 5,28
A<B<C P<0.001MDSCC (B) 106 59,41 9,75
PDSCC (C) 11 74,59 9,2
TNM Stage






Stage II (B) 52 48,47 12,99
Stage III (C) 55 51,83 10,15
Stage IV (D) 94 57,17 11,71
Early Stage 68 48,01 12,19
P<0.001
Advanced Stage 149 55,2 11,42
Cervical lymph node 
metastasis
Non-metastatic 141 49,03 10,83
P<0.001
Metastatic 76 60,23 10,99
3 years disease free 
survival (n=217) Non-survived 69 60,82 10,64 P<0.001
Survived 148 49,28 10,97
5 years disease free 
survival (n=150)
Non-survived 69 60,82 10,64
P<0.001
Survived 80 49,25 10,2
Site
Buccal Mucosa 84 52,04 12,34
One-Way  ANOVA 
P=0.374
GB Sulcus 69 53,74 11,82
Tongue 24 53,5 14,43
Retromolar 16 55,89 6,64
Palate 10 56,28 13,89
Labial Mucosa 11 45,79 9,66
Floor of Mouth 3 55,28 15,09
Note:- OSCC: Oral squamous cell carcinoma, WDSCC: Well differentiated squamous cell carcinoma, MDSCC: Moderately differentiated 
squamous cell carcinoma, PDSCC: Poorly differentiated squamous cell carcinoma, TNM: Tumor (T) Nodes (N) and Metastasis (M).
Table 2- Comparative analysis of Ki67 labeling index in clinicopathological and survival of all Oral squamous cell carcinoma
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and five years disease free survival of OSCC patients. 
The three year disease free survival rate of OSCC 
patient significantly higher with low Ki67 LI (96.2%), 
followed by moderate KI67 LI (60.7%) and high Ki67 
LI (37.7%). The five year disease free survival rate 
of OSCC patient significantly higher with low Ki67 LI 
(93.3%), followed by moderate Ki67 LI (46.8%) and 
high Ki67 LI (23.3%). In this study for the first time 
we introduce the range value for ki67 LI in OSCC that 
could be use as prognostic indicator for survival and 
to decide the treatment regime.
The mean of Ki-67 LI, was significantly higher 
in OSCC patients survived for less than 3 years as 
compared to diseases free survived OSCC patients 
more than 3 years. Similarly, the mean of Ki-67 LI, was 
significantly higher in OSCC patients survived for less 
than 5 years as compared to diseases free survived 
OSCC patients more than 5 years. It has been noticed 
in previous studies9,24-26 that K67 expression in OSCC 
was identified as prognostic factor for survival rate. 
However, several other studies27-30 have described 
no association between higher cell proliferation and 
survival. Recently, Jing, et al.9 (2019) studied Ki67 
expression in large cohort of 298 OSCC and found that 
Ki67 expression was independent prognostic marker in 
OSCC patients. Ki67 expression was also found to be 
prognostic marker in oropharyngeal and OSCC with a 
lager cohort of 239 cases.26 Therefore, it is summarize 
that the increase in Ki67 expression associated with a 
poor prognosis of OSCC.  It was also suggested that 
Ki67 is an indicator for treatment failure in OSCC.9,26 
Thus, it was further strengthen that the high cell 
proliferation identified by Ki67 antigen expression is 
a reliable prognostic marker in oral cancer.
In this study, a significant increase in Ki-67 LI 
was observed from WDSCC to MDSCC to PDSCC. This 
results was in agreement with previous studies9,31-35 
and revealed that as the Ki67 LI increases with 
poorer the degree of tumor cell differentiation. In 
contrast, few studies29,36 failed to show correlation of 
Ki67 LI and degree of differentiation. Disparity in the 
methodology, assessment of Ki67 immunoreactivity, 
and sample size may result in these conflicting results. 
Higher expression of Ki67 protein was discovered in 
undifferentiated/poorly differentiated squamous cells 
carcinoma. Therefore, results of the present study 
further strengthen the fact that, the Ki67 LI could be 
considered as useful potential biomarker in grading 
the OSCC. 
The mean of Ki-67 LI was significantly higher in 
metastatic as compared to non-metastatic OSCC. 
Other studies3,25,32,36 found insignificant correlation with 
cell proliferation and cervical lymph node metastasis, 
which are not in accordance with this study results. In 
this study large cohort of OSCC was used and results 
are in accordance with previous studies.9,28,33,37,38 
This finding may implicate that tumors with high cell 
proliferation index may point out towards aggressive 
behavior of a tumour and a potential for metastasis. 
In the present study, Ki67 LI was significantly 
higher in TNM stage IV as compared to stage III. 
However, non-significant difference of ki67 LI was 
found amongst stage I, stage II and stage III. The 
previous studies3,30,32,34,36 showed no significant 
association between Ki67LI and clinical TNM staging. 
Figure 2- Photomicrograph showing Ki67 antigen expression 
(Ki67 labeling index) in oral squamous cell carcinoma a) Low Ki67 
labeling index (≤45), b) Moderate Ki67 labeling index (46 to 60) 
and c) High Ki67 labeling index (≥61).  (Immunohistochemistry; 
Magnification X100)
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Interestingly, on broadly categories TNM staging, the 
mean Ki67 LI was significantly higher in advanced 
stage OSCC as compared to early stage OSCC. These 
findings are in agreement with previous studies28,33 
suggesting that the increased Ki67 LI indicates the 
higher intrinsic growth potential of the tumor resulting 
in advance TNM staging.
In accordance with previous studies37,38 the result of 
this study have also showed non-significant difference 
of Ki67 LI amongst site of OSCC. 
In this study the Ki67 LI was significantly 
higher with respect to adverse clinicopathological 
parameters such as histopathological grading, clinical 
TNM staging, cervical lymph node metastasis and 
3 as well as 5 years disease free survival of OSCC. 
Thus, it can be suggested that assessment of cell 
Figure 3- The Kaplan-Meier curve for 3 years disease free survival rate for oral squamous cell carcinoma with respect to 1: Low Ki67 
labeling index (≤45), 2: Moderate Ki67 labeling index (46 to 60) and 3: High Ki67 labeling index (≥61)
Figure 4- The Kaplan-Meier curve for 5 years disease free survival rate for oral squamous cell carcinoma with respect to 1: Low Ki67 
labeling index (≤45), 2: Moderate Ki67 labeling index (46 to 60) and 3: High Ki67 labeling index (≥61)
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proliferative activity by quantitative measurement of 
Ki67 positive neoplastic epithelial cells in individual 
invasive OSCC, may thus reveal unique, predictive 
information on clinical outcome, prognosis and 
deciding treatment modalities. Nevertheless, taking 
into consideration the extensive heterogeneity of 
tumors, it is recommended further research with 
standardized uniform immunohistochemistry protocol 
for Ki67 expression and large cohort of OSCC with 5 to 
10 years follow up data to validate the range of Ki67LI 
for prognosis and treatment outcome.
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